[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100510212":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":10,"responsibleParty":31,"collaborators":10,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":10,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":10,"enrollmentInfo":43,"targetDuration":10,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":55,"overallStatus":57,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":10},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All enrolled patients.",null,"All patient who signed the consent form for participation to the study.",[13],"Drug: Duvelisib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Duvelisib","This is a real-word. The treatment options are individualized according to the diagnosis and treatment experience of doctors in each center, diagnosis and treatment specifications and individual conditions of patients.",[9],[21],"Copiktra",[23],{"name":24,"affiliation":5,"role":25},"Weili Zhao, PhD","PRINCIPAL_INVESTIGATOR",[27],{"name":24,"role":28,"phone":29,"phoneExt":10,"email":30},"CONTACT","021-64370045","zwl_trial@163.com",{"type":25,"investigatorFullName":32,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Zhao Weili","Principal Investigator","100510212","chantreal-world-study-of-duvelisib-in-the-treatment-of-non-hodgkins-lymphoma-nhl-100510212",false,"NCT05923502","(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)","(CHANT)A Prospective, Multicenter, Non-interventionistic Real-world Study of Duvelisib Capsules in the Treatment of Non-Hodgkin's Lymphoma (NHL).","Inclusion Criteria:\n\n* To participate in the study voluntarily and sign the informed consent (ICF), with good compliance and cooperative visits;\n* Patients must be ≥ 18 years of age (Based on the date of signing the informed Consent (ICF));\n* Pathologically or Histologically confirmed NHL including but not limited to the following subtypes:\n\n  1. Follicular lymphoma (FL);\n  2. Chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma or Richter syndrome (CLL\u002FSLL or RS);\n  3. Marginal zone lymphoma (MZL);\n  4. Peripheral T-cell lymphoma (PTCL);\n  5. Diffuse large B-cell lymphoma (DLBCL).\n* Patients who have received at least one systemic chemotherapy and have relapsed at the end of the treatment or progressed during treatment;\n* Must have adequate organ function defined by the following laboratory parameters:\n\n  1. Bone marrow function: Absolute neutrophil count (ANC) ≥ 0.5 × 10\\^9\u002FL, Platelet count (PLT) ≥ 25 × 10\\^9\u002FL, blood transfusion can be used before medication;\n  2. Liver and kidney function: Aspartate transaminase (AST) and alanine aminotransferase (ALT)≤5.0 × ULN;\n  3. Estimated creatinine clearance value ≥30 milliliters\u002Fminute (as determined by the Cockcroft-Gault method).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;\n* Patients with infections should be treated first and then considered for enrollment when the infection is under control.\n\nExclusion Criteria:\n\n* Female subjects who are pregnant or breastfeeding;\n* Estimated lifetime is less than 3 months;\n* In the investigator's judgment, patients who require but are unable to receive prophylactic treatment for Pneumocystis or herpes simplex virus (HSV) prior to trial drug treatment;\n* History or concurrent condition of interstitial lung disease of any severity and\u002For severely impaired lung function;\n* Prior history of drug-induced colitis or drug-induced interstitial pneumonia;\n* Known hypersensitivity to Duvelisib or its excipients;\n* Administration of medications or foods that are strong inhibitors or inducers of CYP3A beginning 2 weeks prior to the first dose of Duvelisib;\n* According to the judgement of the researcher, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of the study.","ALL","18 Years",{"count":44,"type":45},200,"ESTIMATED","OBSERVATIONAL","This is a multicenter, non-interventional and prospective real-world study to evaluate the efficacy and safety of Duvelisib capsules in patients with non-Hodgkin's lymphoma.",[49,50,51,52,53,54],"Follicular Lymphoma","Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma","Richter Syndrome","Marginal Zone Lymphoma","Peripheral T Cell Lymphoma","Diffuse Large B Cell Lymphoma",[56],"NHL; Duvelisib","NOT_YET_RECRUITING","2023-10-18",{"date":60,"type":61},"2023-10-23","ACTUAL",{"date":63,"type":45},"2023-10-20",{"date":65,"type":45},"2027-11-30",{"name":5,"class":6}]